Skip to main content

Table 1 Number of participants enrolled and finishing follow-up and characteristics at baseline

From: Efficacy and safety of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017

  Benguela Zaire Lunda Sul
DPb ASAQa ALa ASAQa ALa DPb
Enrollment and follow-up
 Enrolled, n 100 105 100 98 105 100
 Lost to follow up, n (%) 5 (5) 2 (2) 3 (3) 5 (5) 5 (5) 7 (7)
 Excluded, n (%) 10 (10) 12 (11) 3 (3) 3 (3) 9 (9) 4 (4)
 Reached study endpoint, n (%) 85 (85) 91 (87) 94 (94) 90 (92) 91 (87) 89 (89)
Participant characteristics at baseline
 Median age, years (range) 7.1 (2–12) 6.3 (2–12) 3 (0.5–5) 2.7 (0.8–5) 3.3 (0.6–5) 3 (0.5–5)
 Median weight, kg (range) 20 (9–48) 19 (10–52) 12 (7–20) 12 (7–19) 12 (6–20) 12 (6–19)
 Percent female (%) 53 53 46 55 54 47
 Median day 0 parasitaemia, parasites/µL (range) 25,940 (1218–95,585) 31,399 (1242–97,167) 47,607 (2175–182,138) 31,215 (2848–184,243) 22,340 (2162–122,064) 19,812 (3316–184,465)
 Median day 0 haemoglobin, g/dL (range) 10.5 (8.1–13.9) 10.7 (8.1–15.1) 10.1 (8.1–13.0) 9.7 (8.1–13.0) 9.5 (8.1–12.8) 9.3 (8.1–14.9)
  1. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
  2. a28-day follow-up
  3. b42-day follow-up